Skip to content
Search AI Powered

Latest Stories

Drug alert issued for Diazepam 2mg

The Medicines and Health products Regulatory Agency (MHRA) has issued a medicines defect alert for Accord's sugar free Diazepam 2mg/5ml oral solution.

Accord-UK has informed the MHRA that important safety warnings for the excipient Propylene glycol are missing from the patient information leaflet (PIL) used in the above batches, including the batches waiting QP certification. The warnings should be present in accordance with the current annex to the excipient guidelines.


“Additionally, the warnings for sorbitol need updating although similar warnings are already present. The product is not subject to recall due to supply and shortage considerations,” the regulator has said in its latest update.

The drug manufacturer has added following excipient warnings to the PIL for future batches.

  • Diazepam oral solution contains 409mg Propylene glycol per 5ml. If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they use other medicines that contain propylene glycol or alcohol. If you suffer from a liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.
  • Diazepam oral solution contains 1.91g to 2.58g of sorbitol per 5ml solution. Sorbitol is a source of fructose. If your doctor has told you that you (or your child) have an intolerance to some sugars or if you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. Sorbitol may cause gastrointestinal discomfort and mild laxative effect. Calorific value 2.6 kcal/g sorbitol.

Product details

Diazepam 2mg/5ml Oral Solution Sugar Free (Accord-UK Ltd) (PL 0142/0103)

Batch NumberExpiry DatePack SizeLiveryFirst Distributed
I5465531/07/2021100mlAccord-UK Ltd11/12/2019
I5479730/09/2021100mlAccord-UK Ltd17/03/2020
I5479830/09/2021100mlAccord-UK Ltd17/03/2020
I5522328/02/2022100mlAccord-UK Ltd12/05/2020
I5539930/04/2022100mlAccord-UK Ltd27/07/2020
I5550631/05/2022100mlAccord-UK Ltd16/09/2020
I5562331/07/2022100mlAccord-UK Ltd23/11/2020
I5589431/10/2022100mlAccord-UK Ltd25/01/2021
I5446830/04/2021100mlAlmus24/09/2019
I5479930/09/2021100mlAlmus17/03/2020
I5540830/04/2022100mlAlmus02/09/2020
I5562431/07/2022100mlAlmus22/01/2021

The following batches have been packed and are waiting QP certification

Batch NumberExpiry DatePack SizeDescriptionFirst Distributed
I5613131/01/2023100mlAccord-UK Ltd
I5605531/12/2022100mlAccord-UK Ltd
I5613231/01/2023100mlAccord-UK Ltd

Healthcare professionals are suggested to provide necessary information to the patients on the issue. “There is no risk to product quality as a result of this issue, therefore the associated batches are not being recalled at this time. The product is not subject to recall due to supply and shortage considerations,” the MHRA said.

“Accord-UK have confirmed that they will be providing hard copies of the updated PIL to wholesalers and pharmacies so that any remaining stock in the dispensary can be supplemented with the updated PIL information," it said.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less